EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Use of soluble guanylyl cyclase stimulators in heart failure therapy—a mode of action perspective

Frank Ruschitzka, Robert Lukowski iD, Stefano Corda, Christian Meier, Peter Sandner

ESC Heart Failure · 2026

DOI: 10.1093/eschf/xvag117 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ESC Heart Failure, 2026. Verfasst von Frank Ruschitzka und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Heart Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Heart Failure, Soluble Guanylyl Cyclase. Die Arbeit nennt 165 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer AG, Wuppertal, Germany.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite recent advances in pharmacological treatment, chronic heart failure (HF) is associated with significant morbidity and mortality, and further treatment options are needed. Intact nitric oxide (NO)–soluble guanylyl cyclase (sGC)–cyclic guanosine monophosphate (cGMP) signalling is a prerequisite of cardiovascular health. cGMP produced by NO/NO–sGC acts as a second messenger molecule via various downstream targets, which influence a broad spectrum of critical physiological parameters. Impairment of this cascade in the cardiovascular system is considered an important pathomechanism in HF. This review examines pharmacological therapies that act through the NO–sGC–cGMP signalling pathway. We will focus on the molecular mode(s) of action of NO-independent but haem-dependent sGC stimulators, and will examine evidence from preclinical studies demonstrating cardiovascular benefits of these therapies and their increasing number of effects on other susceptible tissues and organs, which together could contribute to clinical outcomes in HF. The sGC stimulator vericiguat may be considered, in addition to standard therapy, for adults with symptomatic HF with reduced ejection fraction following a worsening event. The findings from pivotal clinical trials that led to these recommendations will be outlined and classified in terms of their significance for different subpopulations. These include the Phase 3 VICTORIA and VICTOR trials. Finally, further research areas and ongoing studies designed to address existing gaps in our knowledge regarding vericiguat and related drugs will be highlighted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureSoluble Guanylyl CyclaseHumansSignal TransductionAnimalsCyclic GMPNitric Oxide

Stichwörter der Autor:innen

Cyclic guanosine monophosphateHeart failureSoluble guanylyl cyclaseVericiguatsGC stimulators

Substanzen

Soluble Guanylyl CyclaseCyclic GMPNitric Oxide

Autor:innen und Institutionen

  • Department of Cardiology, University Heart Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
  • Department of Cardiology, Center for Translational and Experimental Cardiology (CTEC), University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Institute of Pharmacy, Pharmacology, Toxicology and Clinical Pharmacy, University of Tübingen, Tübingen, Germany.
  • BCC AG, Pharmaceuticals, Bayer Consumer Care AG, Basel, Switzerland.
  • Global Medical Affairs, Bayer AG, Berlin, Germany.
  • Research & Early Development, Bayer AG, Pharmaceuticals, Aprather Weg 18a, 42113 Wuppertal, Germany & Hannover Medical School, Hannover, Germany.

ORCID-Profile: Robert Lukowski

Förderung

  • Bayer AG, Wuppertal, Germany

Zitieren

APA

Ruschitzka, F., Lukowski, R., Corda, S., Meier, C., & Sandner, P. (2026). Use of soluble guanylyl cyclase stimulators in heart failure therapy—a mode of action perspective. ESC Heart Failure. https://doi.org/10.1093/eschf/xvag117

Vancouver

Ruschitzka F, Lukowski R, Corda S, Meier C, Sandner P. Use of soluble guanylyl cyclase stimulators in heart failure therapy—a mode of action perspective. ESC Heart Failure. 2026. doi:10.1093/eschf/xvag117

BibTeX
@article{Ruschitzka2026,
  author = {Ruschitzka, Frank and Lukowski, Robert and Corda, Stefano and Meier, Christian and Sandner, Peter},
  title = {Use of soluble guanylyl cyclase stimulators in heart failure therapy—a mode of action perspective},
  journal = {ESC Heart Failure},
  year = {2026},
  doi = {10.1093/eschf/xvag117}
}
Kostenlos starten →